Spinal muscular atrophy is a genetic neuromuscular disease that causes progressive muscle weakness due to the loss of motor neurons in the spinal cord. Scholar Rock said apitegrom ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating ...

The Muscular Dystrophy Association (MDA) celebrates today's announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose Regimen of SPINRAZA(R) (nusinersen) for the treatment ...

The Muscular Dystrophy Association (MDA) celebrates today’s announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose Regimen of SPINRAZA® (nusinersen) for the treatment ...

Scholar Rock (SRRK) stock jumps as the company resubmits its marketing application for its lead drug, apitegromab, against ...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in ...

Biogen Inc. BIIB shares are up on Monday following the FDA’s approval of a new high-dose regimen for Spinraza (nusinersen), a ...

After a surprise rejection in September last year, the FDA has signed off on a high-dose formulation of Biogen’s spinal muscular atrophy drug Spinraza. The approval, announced Monday, will allow a ...

It's well known that spaceflight causes muscle atrophy and other biological changes in reduced gravity, and especially in ...

Children born with a rare neuromuscular disorder are being given another chance in life thanks to a new treatment experts are ...